Skip to main content

Congress of Neurological Surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods

Abstract

Introduction

The management of glioblastoma at the time of progression is an important facet of all physicians involved in neuro-oncology. This is an update of the evidence-based guidelines for management of progressive glioblastoma published by the Congress of Neurological Surgeons and American Association of Neurological Surgeons in 2014.

Methods

The medical literature from July 1, 2012 through March 31, 2019 was searched in MEDLINE® and Embase® and the Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Registry, and Cochrane Database of Abstracts of Reviews of Effects to determine if information was available to update, modify or create new recommendations related to imaging, cytoreductive surgery, neuropathology, radiotherapy, cytotoxic chemotherapy, targeted therapy, and immunotherapy.

Results

The writing group utilized the information from the updated literature search to formulate recommendations that were exclusively evidence based and not founded on potentially biased consensus or expert opinion.

Conclusion

The series of guideline documents provides an update of the information and recommendations that could be derived in the 2014 version. It sets a benchmark as to what we really know about the management of this difficult disease. It also provides clues to key investigations that are necessary to move us toward truly effective disease control.

This is a preview of subscription content, access via your institution.

Fig. 1

Data availability

The author has ensured all data and materials as well as software applications or custom code supports their published claims and comply with field standards.

References

  1. Olson JJ, Ryken TC, Kalkanis SN (2014) The management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline: introduction and rationale. J Neuro-oncol 118:429–434. https://doi.org/10.1007/s11060-013-1329-6

    Article  Google Scholar 

  2. Ryken CR, Aygun N, Morris J, Schweizer M, Nair R, Spracklen C, Kalkanis SH, Olson JJ (2014) The role of imaging in the management of progressive glioblastoma. J Neuro-oncol 118:435–460. https://doi.org/10.1007/s11060-013-1330-0

    CAS  Article  Google Scholar 

  3. Brat DJ, Ryken TC, Kalkanis SN, Olson JJ (2014) The role of neuropathology in the management of progressive glioblastoma. J Neuro-oncol 118:461–478. https://doi.org/10.1007/s11060-013-1331-z

    CAS  Article  Google Scholar 

  4. Ryken TC, Kalkanis SN, Buatti JM, Olson JJ (2014) The role of cytoreductive surgery in the management of progressive glioblastoma. J Neuro-oncol 118:479–488. https://doi.org/10.1007/s11060-013-1336-7

    Article  Google Scholar 

  5. Ryu S, Buatti JM, Morris A, Kalkanis SN, Ryken TC, Olson JJ (2014) The role of radiotherapy in the management of progressive glioblastoma. J Neuro-oncol 118:489–499. https://doi.org/10.1007/s11060-013-1337-6

    CAS  Article  Google Scholar 

  6. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN (2014) The role of cytotoxic chemotherapy in the management of progressive glioblastoma. J Neuro-oncol 118:501–555. https://doi.org/10.1007/s11060-013-1338-5

    CAS  Article  Google Scholar 

  7. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN (2014) The role of targeted therapies in the management of progressive glioblastoma. J Neuro-oncol 118:557–599. https://doi.org/10.1007/s11060-013-1339-4

    CAS  Article  Google Scholar 

  8. The National Acadamies of Science Engineering Medicine (2011) Clinical practice guidelines we can trust. https://www.nap.edu/catalog/13058/clinical-practice-guidelines-we-can-trust. Accessed July 26, 2021. https://doi.org/10.17226/13058

  9. Strauss SB, Meng A, Ebani EJ, Chiang GC (2019) Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse. Radiation Necrosis Radiol Clin North Am 57:1199–1216. https://doi.org/10.1016/j.rcl.2019.07.003

    Article  PubMed  Google Scholar 

  10. Schipmann S, Schwake M, Suero Molina E, Stummer W (2019) Markers for identifying and targeting glioblastoma cells during surgery. J Neurol Surg 80:475–487. https://doi.org/10.1055/s-0039-1692976

    Article  Google Scholar 

  11. Le Rhun E, Preusser M, Roth P et al (2019) Molecular targeted therapy of glioblastoma. Canc Treatment Rev Fecci PI, Sampson JH (2019) The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg 131:657–666. https://doi.org/10.1016/j.ctrv.2019.101896

    CAS  Article  Google Scholar 

  12. Cao Y, Tseng CL, Balter JM, Teng F, Parmar HA, Sahgal A (2017) MR-guided radiation therapy: transformative technology and its role in the central nervous system. Neuro-Oncol 19(2):16–29. https://doi.org/10.1093/neuonc/nox006

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The guidelines task force would like to acknowledge the Congress of Neurological Surgeons Guidelines Committee for their contributions throughout the development of the guideline, and the American Association of Neurological Surgeons/Congress of Neurological Surgeons Joint Guidelines Review Committee for their review, comments, and suggestions throughout peer review, as well as the contributions of Trish Rehring, MPH, CHES, Senior Manager of Clinical Practice Guidelines for the CNS, and Mary Bodach, MLIS, from the Congress of Neurological Surgeons Guidelines Office for organizational assistance and reference librarian services, respectively as well as Jeremy Kupsco, PhD, Informationist, Emory University, for their valuable input as Medical Research Librarians. Throughout the review process, the reviewers and authors were blinded from one another. At this time the guidelines task force would like to acknowledge the following individual peer reviewers for their contributions: John O’Toole, MD, Brian Howard, MD, Jamie Van Gompel, MD, Howard Silberstein, MD, Navid Redjal, MD and Shawn Hervey-Jumper, MD.

Funding

These guidelines were funded exclusively by the Congress of Neurological Surgery and the Joint Section on Tumors of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons, which received no funding from any outside commercial sources to support the development of this document.

Author information

Authors and Affiliations

Authors

Contributions

The author listed on this publication agrees with the content included and gives explicit consent to the submission of this publication. The author obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work was submitted. The author whose name appear on the submission: (1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; (2) drafted the work or revised it critically for important intellectual content; (3) approved the version to be published; and (4) agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Jeffrey J. Olson.

Ethics declarations

Conflict of interest

Jeffrey J. Olson has no conflict of interest. All Guideline Task Force members were required to disclose all potential COIs prior to beginning work on the guideline, using the COI disclosure form of the AANS/CNS Joint Guidelines Review Committee. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination and participation on the task force. The CNS Guidelines Committee and Guideline Task Force Chair may approve nominations of task force members with possible conflicts and restrict the writing, reviewing, and/or voting privileges of that person to topics that are unrelated to the possible COIs. To reiterate, the authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this series of articles.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Sponsors: Congress of Neurological Surgeons (CNS) and the Section on Tumors.

Endorsement: Reviewed for evidence-based integrity and endorsed by the American Association of Neurological Surgeons and Congress of Neurological Surgeons.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Olson, J.J. Congress of Neurological Surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods. J Neurooncol 158, 133–137 (2022). https://doi.org/10.1007/s11060-021-03850-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-021-03850-3

Keywords

  • Glioblastoma
  • Guidelines
  • Therapy